There has been a growing trend of life science manufacturers collaborating with local governments (e.g., at the municipal and prefectural level) in Japan during the past 3-5 years. This trend is observed not only with domestic manufacturers but among foreign…
HOME > COLUMN
COLUMN
-
Maurer's Healthcare Insight (126)
November 8, 2010
-
Maurer's Healthcare Insight (125)
October 25, 2010
-
Maurer's Healthcare Insight (124)
October 11, 2010
-
Maurer's Healthcare Insight (123)
July 12, 2010
-
Maurer's Healthcare Insight (122)
May 31, 2010
-
Maurer's Healthcare Insight (121)
May 3, 2010
-
Maurer's Healthcare Insight (120)
April 12, 2010
-
Maurer's Healthcare Insight (119)
March 1, 2010
-
Maurer's Healthcare Insight (118)
January 4, 2010
-
Maurer's Healthcare Insight (117)
December 14, 2009
-
Maurer's Healthcare Insight (116)
November 30, 2009
-
Maurer's Healthcare Insight (115)
November 16, 2009
-
Maurer's Healthcare Insight (114)
October 26, 2009
-
Maurer's Healthcare Insight (113)
October 5, 2009
-
Maurer's Healthcare Insight (112)
September 14, 2009
-
Maurer's Healthcare Insight (111)
August 24, 2009
-
Maurer's Healthcare Insight (110)
July 27, 2009
-
Maurer's Healthcare Insight (109)
June 22, 2009
-
Maurer's Healthcare Insight (108)
May 18, 2009
-
Maurer's Healthcare Insight (107)
April 27, 2009
ページ
Shionogi’s COVID-19 pill ensitrelvir failed to clear the second round of review by a key advisory panel on July 20. The session drew a great deal of attention since the drug is the first candidate for the application of Japan’s…
The average ratio of females in managerial posts at Japanese drug makers has finally reached a double-digit number, at 10.0%, a Jiho survey found. However, this is still well below a near-25% ratio logged by foreign players operating in the…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…
A total of 15 new drugs (APIs) joined the NHI price list in 2021 with peak sales forecasts topping at 10 billion yen, many of them in the area of orphan diseases and with few mega launches, according to a…